Peterson Wealth Management Purchases 1,065 Shares of Eli Lilly and Company (NYSE:LLY)

Peterson Wealth Management increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,951 shares of the company's stock after acquiring an additional 1,065 shares during the period. Eli Lilly and Company accounts for about 2.3% of Peterson Wealth Management's holdings, making the stock its 17th largest position. Peterson Wealth Management's holdings in Eli Lilly and Company were worth $3,823,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $8,407,908,000. Proficio Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 100,387.1% in the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after acquiring an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP increased its position in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the period. Capital International Investors raised its stake in Eli Lilly and Company by 23.2% during the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Eli Lilly and Company in the 4th quarter valued at $1,240,653,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 3.9 %

Shares of Eli Lilly and Company stock traded up $31.00 during trading on Friday, hitting $825.10. 6,056,616 shares of the company were exchanged, compared to its average volume of 3,482,067. The firm has a market capitalization of $782.34 billion, a P/E ratio of 70.46, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The firm's fifty day moving average price is $825.36 and its 200 day moving average price is $816.37. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the company posted $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research report on Friday, January 17th. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday. UBS Group cut their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday. Finally, Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,002.80.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.